[{"address1": "500 North Beacon Street", "address2": "4th Floor", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "857 285 5300", "website": "https://www.kymeratx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 218, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bruce L. Booth DPHIL, Ph.D.", "age": 50, "title": "Co-Founder & Independent Chairman", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 70000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nello  Mainolfi M.D., Ph.D.", "age": 45, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 1226500, "exercisedValue": 1110312, "unexercisedValue": 37845672}, {"maxAge": 1, "name": "Mr. Bruce N. Jacobs CFA", "title": "Chief Financial Officer", "fiscalYear": 2024, "totalPay": 754540, "exercisedValue": 703665, "unexercisedValue": 9900757}, {"maxAge": 1, "name": "Dr. Jeremy G. Chadwick Ph.D.", "age": 61, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 719400, "exercisedValue": 0, "unexercisedValue": 838368}, {"maxAge": 1, "name": "Dr. Jared A. Gollob M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 768400, "exercisedValue": 3280617, "unexercisedValue": 6586792}, {"maxAge": 1, "name": "Ms. Justine E. Koenigsberg", "title": "Vice President of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian R. Adams J.D.", "age": 50, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen  Weisbach", "title": "Head of People & Culture", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juliet  Williams B.A Ph.D.", "title": "Head of Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Noah  Goodman M.B.A.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 60.46, "open": 60.2, "dayLow": 57.32, "dayHigh": 61.61, "regularMarketPreviousClose": 60.46, "regularMarketOpen": 60.2, "regularMarketDayLow": 57.32, "regularMarketDayHigh": 61.61, "payoutRatio": 0.0, "beta": 2.27, "forwardPE": -19.237944, "volume": 682699, "regularMarketVolume": 682699, "averageVolume": 730726, "averageVolume10days": 663870, "averageDailyVolume10Day": 663870, "bid": 59.61, "ask": 59.97, "bidSize": 1, "askSize": 1, "marketCap": 4277701632, "fiftyTwoWeekLow": 19.445, "fiftyTwoWeekHigh": 63.96, "allTimeHigh": 91.92, "allTimeLow": 9.6, "priceToSalesTrailing12Months": 95.67448, "fiftyDayAverage": 48.8227, "twoHundredDayAverage": 40.0179, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3697970176, "profitMargins": 0.0, "floatShares": 46969631, "sharesOutstanding": 71497597, "sharesShort": 8085396, "sharesShortPriorMonth": 8164580, "sharesShortPreviousMonthDate": 1756425600, "dateShortInterest": 1759190400, "sharesPercentSharesOut": 0.11310001, "heldPercentInsiders": 0.025109999, "heldPercentInstitutions": 1.11552, "shortRatio": 8.66, "shortPercentOfFloat": 0.1396, "impliedSharesOutstanding": 71497597, "bookValue": 13.769, "priceToBook": 4.3452682, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -275433984, "trailingEps": -3.49, "forwardEps": -3.11, "enterpriseToRevenue": 82.708, "enterpriseToEbitda": -12.122, "52WeekChange": 0.28500855, "SandP52WeekChange": 0.13837254, "quoteType": "EQUITY", "currentPrice": 59.83, "targetHighPrice": 92.0, "targetLowPrice": 53.0, "targetMeanPrice": 66.0, "targetMedianPrice": 64.5, "recommendationMean": 1.2381, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 20, "totalCash": 665444992, "totalCashPerShare": 9.307, "ebitda": -305056000, "totalDebt": 85714000, "quickRatio": 8.059, "currentRatio": 8.32, "totalRevenue": 44711000, "debtToEquity": 8.823, "revenuePerShare": 0.564, "returnOnAssets": -0.19919, "returnOnEquity": -0.33257, "grossProfits": -246159008, "freeCashflow": -153841376, "operatingCashflow": -251008000, "revenueGrowth": -0.553, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -7.36816, "financialCurrency": "USD", "symbol": "KYMR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Kymera Therapeutics, Inc.", "longName": "Kymera Therapeutics, Inc.", "cryptoTradeable": false, "postMarketChangePercent": 0.0, "postMarketPrice": 59.83, "postMarketChange": 0.0, "regularMarketChange": -0.629997, "regularMarketDayRange": "57.32 - 61.61", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 730726, "fiftyTwoWeekLowChange": 40.385002, "fiftyTwoWeekLowChangePercent": 2.0768836, "fiftyTwoWeekRange": "19.445 - 63.96", "fiftyTwoWeekHighChange": -4.1299973, "fiftyTwoWeekHighChangePercent": -0.06457157, "fiftyTwoWeekChangePercent": 28.500854, "earningsTimestamp": 1754884800, "earningsTimestampStart": 1762432200, "earningsTimestampEnd": 1762432200, "earningsCallTimestampStart": 1754915400, "earningsCallTimestampEnd": 1754915400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.49, "epsForward": -3.11, "epsCurrentYear": -3.41444, "priceEpsCurrentYear": -17.52264, "fiftyDayAverageChange": 11.007301, "fiftyDayAverageChangePercent": 0.22545458, "twoHundredDayAverageChange": 19.812103, "twoHundredDayAverageChangePercent": 0.49508104, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-08-21", "averageAnalystRating": "1.2 - Strong Buy", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1598016600000, "corporateActions": [], "postMarketTime": 1760733117, "regularMarketTime": 1760731201, "exchange": "NGM", "messageBoardId": "finmb_542085131", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -1.04201, "regularMarketPrice": 59.83, "displayName": "Kymera Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-10-18"}]